



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/766,312 | 01/29/2004 | David M. Schuster | 38266-0012 | 1253 |

26633 7590 08/28/2006

HELLER EHRMAN WHITE & MCAULIFFE LLP
1717 RHODE ISLAND AVE, NW
WASHINGTON, DC 20036-3001

| |
|----------|
| EXAMINER |
|----------|

THOMAS, DAVID C

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1637

DATE MAILED: 08/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|------------------------------|--------------------------------------|--|--|
| Office Action Summary | Application No. 10/766,312 | Applicant(s) SCHUSTER ET AL. | |
| | Examiner David C. Thomas | Art Unit 1637 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-19 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. ____. |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

1. Claims 1-19 will be examined on the merits.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

3. Claims 1-4, 7-12, 18, and 19 are rejected under 35 U.S.C. 102(a) as being anticipated by Gerard et al. (U.S. Patent Pub. No. 2002/0081581).

Gerard teaches a method for amplifying a nucleic acid molecule (see paragraph 2 for overview), said method comprising

incubating an RNA template (such as messenger RNA, paragraph 12, lines 1-5 and 11-21) with a composition comprising (a) a buffer (buffer suitable for amplification, paragraph 11, line 9 and paragraph 193, lines 1-8), (b) two or more proteins having reverse transcriptase (RT) activity (two or more polypeptides with RT activity, paragraph 11, lines 4-7) and (c) at least one DNA polymerase (paragraph 11, line 9 and paragraph 13, lines 15-18);

under conditions which substantially relieve reverse-transcriptase-mediated inhibition of DNA polymerase activity and which are sufficient to amplify a DNA molecule complementary to all or a portion of said RNA template (double-stranded DNA molecule products are produced which are complementary to all or a portion of the

Art Unit: 1637

nucleic acid templates, also indicating that the DNA polymerase was not substantially inhibited, paragraph 12, lines 6-11).

With regard to claim 2, Gerard teaches a method for amplifying a nucleic acid molecule wherein said two or more proteins having reverse transcriptase activity comprise:

a first reverse transcriptase enzyme in which the reverse transcriptase activity resides in a single polypeptide (such as the RT from Moloney murine leukemia virus, paragraph 7, lines 1-4 and paragraph 11, lines 17-18); and

a second reverse transcriptase enzyme in which the reverse transcriptase activity resides in a dimeric or multimeric structure (such as the RT from Avian Myeloblastosis Virus, AMV, paragraph 7, lines 23-35 and paragraph 11, lines 20-21).

With regard to claim 3, Gerard teaches a method for amplifying a nucleic acid molecule wherein said first reverse transcriptase enzyme in which the reverse transcriptase activity resides in a single polypeptide is Moloney murine leukemia virus (M-MLV) reverse transcriptase or a derivative thereof having reduced RNase H activity (M-MLV H⁻ RT with reduced or substantially reduced RNase H activity, paragraph 11, lines 14-18) and said second reverse transcriptase enzyme in which the reverse transcriptase activity resides in a dimeric or multimeric structure is AMV reverse transcriptase or a derivative thereof having reduced RNase H activity (AMV H⁻ RT with reduced or substantially reduced RNase H activity, paragraph 11, lines 14-20).

Art Unit: 1637

With regard to claim 4, Gerard teaches a method for amplifying a nucleic acid molecule wherein said composition comprises a first primer and a second primer (one or more primers is used in composition for amplification, paragraph 14, lines 25-27) and,

wherein said first primer is suitable for facilitating synthesis of first strand cDNA from said RNA template (first nucleic acid molecule is made complementary to RNA template, paragraph 13, lines 6-9), and wherein the combination of said first and said second primer is suitable for amplifying said first strand cDNA (incubating first nucleic acid molecule with composition containing primers and DNA polymerase, column 14, lines 21-27, results in making second nucleic acid molecule and multiple copies of double-stranded molecule, column 13, lines 9-14 and column 14, lines 1-16).

With regard to claim 7, Gerard teaches a method for accurately quantifying a nucleic acid molecule in an essentially sequence-independent manner (double-stranded products are produced that are complementary to template, which is indicative of accurate quantification of input template nucleic acid, column 14, lines 1-16), said method comprising

incubating an RNA template (such as messenger RNA, paragraph 12, lines 1-5 and 11-21) with a composition comprising (a) a buffer (buffer suitable for amplification, paragraph 11, line 9 and paragraph 193, lines 1-8), (b) two or more proteins having reverse transcriptase (RT) activity (two or more polypeptides with RT activity, paragraph 11, lines 4-7) and (c) at least one DNA polymerase (paragraph 11, line 9 and paragraph 13, lines 15-18), and (d) a first primer and a second primer (one or more primers is used in composition for amplification, paragraph 14, lines 25-27),

wherein said first primer is suitable for facilitating synthesis of first strand cDNA from said RNA template (first nucleic acid molecule is made complementary to RNA template, paragraph 13, lines 6-9), and wherein the combination of said first and said second primer is suitable for amplifying said first strand cDNA (incubating first nucleic acid molecule with composition containing primers and DNA polymerase, column 14, lines 21-27, results in making second nucleic acid molecule and multiple copies of double-stranded molecule, column 13, lines 9-14 and column 14, lines 1-16), and

wherein said incubation is sufficient to amplify a DNA molecule complementary to all or a portion of said RNA template (double-stranded DNA molecule products are complementary to all or portion of the nucleic acid templates, paragraph 12, lines 6-11).

With regard to claim 8, Gerard teaches a method for the unbiased quantification of a nucleic acid molecule contained in a sample (such as performing RT reaction at higher temperatures to help reduce mRNA secondary structure and improve specificity of primer binding to reduce background signals, paragraph 135, lines 7-19, in order to produce products complementary to template, paragraph 136, lines 1-8), said method comprising

incubating an RNA template (such as messenger RNA, paragraph 12, lines 1-5 and 11-21) with a composition comprising (a) a buffer (buffer suitable for amplification, paragraph 11, line 9 and paragraph 193, lines 1-8), (b) two or more proteins having reverse transcriptase (RT) activity (two or more polypeptides with RT activity, paragraph 11, lines 4-7) and (c) at least one DNA polymerase (paragraph 11, line 9 and paragraph

Art Unit: 1637

13, lines 15-18), and (d) a first primer and a second primer (one or more primers is used in composition for amplification, paragraph 14, lines 25-27),

wherein said first primer is suitable for facilitating synthesis of first strand cDNA from said RNA template (first nucleic acid molecule is made complementary to RNA template, paragraph 13, lines 6-9), and wherein the combination of said first and said second primer is suitable for amplifying said first strand cDNA (incubating first nucleic acid molecule with composition containing primers and DNA polymerase, column 14, lines 21-27, results in making second nucleic acid molecule and multiple copies of double-stranded molecule, column 13, lines 9-14 and column 14, lines 1-16), and

wherein said incubation is sufficient to amplify a DNA molecule complementary to all or a portion of said RNA template (double-stranded DNA molecule products are complementary to all or portion of the nucleic acid templates, paragraph 12, lines 6-11).

With regard to claim 9, Gerard teaches a method for accurately quantifying a nucleic acid molecule (double-stranded products are produced that are complementary to template, which is indicative of accurate quantification of input template nucleic acid, column 14, lines 1-16) wherein said two or more proteins having reverse transcriptase activity comprise:

a first reverse transcriptase enzyme in which the reverse transcriptase activity resides in a single polypeptide (such as the RT from Moloney murine leukemia virus, paragraph 7, lines 1-4 and paragraph 11, lines 17-18); and

a second reverse transcriptase enzyme in which the reverse transcriptase activity resides in a dimeric or multimeric structure (such as the RT from Avian Myeloblastosis Virus, AMV, paragraph 7, lines 23-35 and paragraph 11, lines 20-21).

With regard to claim 10, Gerard teaches a method for accurately quantifying a nucleic acid molecule wherein said first reverse transcriptase enzyme in which the reverse transcriptase activity resides in a single polypeptide is Moloney murine leukemia virus (M-MLV) reverse transcriptase or a derivative thereof having reduced RNase H activity (M-MLV H⁻ RT with reduced or substantially reduced RNase H activity, paragraph 11, lines 14-18) and said second reverse transcriptase enzyme in which the reverse transcriptase activity resides in a dimeric or multimeric structure is AMV reverse transcriptase or a derivative thereof having reduced RNase H activity (AMV H⁻ RT with reduced or substantially reduced RNase H activity, paragraph 11, lines 14-20).

With regard to claim 11, Gerard teaches a method for the unbiased quantification of a nucleic acid molecule contained in a sample (such as performing RT reaction at higher temperatures to help reduce mRNA secondary structure and improve specificity of primer binding to reduce background signals, paragraph 135, lines 7-19, in order to produce products complementary to template, paragraph 136, lines 1-8), wherein said two or more proteins having reverse transcriptase activity comprise:

a first reverse transcriptase enzyme in which the reverse transcriptase activity resides in a single polypeptide (such as the RT from Moloney murine leukemia virus, paragraph 7, lines 1-4 and paragraph 11, lines 17-18); and

a second reverse transcriptase enzyme in which the reverse transcriptase activity resides in a dimeric or multimeric structure (such as the RT from Avian Myeloblastosis Virus, AMV, paragraph 7, lines 23-35 and paragraph 11, lines 20-21).

With regard to claim 12, Gerard teaches a method for the unbiased quantification of a nucleic acid molecule contained in a sample wherein said first reverse transcriptase enzyme in which the reverse transcriptase activity resides in a single polypeptide is Moloney murine leukemia virus (M-MLV) reverse transcriptase or a derivative thereof having reduced RNase H activity (M-MLV H⁻ RT with reduced or substantially reduced RNase H activity, paragraph 11, lines 14-18) and said second reverse transcriptase enzyme in which the reverse transcriptase activity resides in a dimeric or multimeric structure is AMV reverse transcriptase or a derivative thereof having reduced RNase H activity (AMV H⁻ RT with reduced or substantially reduced RNase H activity, paragraph 11, lines 14-20).

With regard to claim 18, Gerard teaches a method for amplifying a nucleic acid molecule wherein said buffer further comprises a sulfur-containing compound and a potassium-containing compound (buffer for synthesis of cDNA molecule may include sulfate forms of TRIS buffer, as well as potassium chloride or acetate paragraph 121, lines 1-13, and also dithiotreitol, paragraph 193, lines 1-8).

With regard to claim 19, Gerard teaches a method for amplifying a nucleic acid molecule wherein said DNA polymerase is a thermostable DNA polymerase (polymerase used for amplification of cDNA is thermostable, paragraph 22, lines 17-20).

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 5, 6, and 13-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gerard et al. (U.S. Patent Pub. No. 2002/0081581) in view of Zhao et al. (U.S. Patent No. 6,300,073).

Gerard teaches the limitations of claims 1-4, 7-12, 18, and 19 as discussed above.

Gerard does not teach a method for amplifying a nucleic acid molecule wherein said buffer comprises an effective amount of at least one glutamate-containing compound, wherein the total glutamate concentration is about 1 mM to about 500 mM, and wherein said at least one glutamate compound is selected from the group

Art Unit: 1637

consisting of glutamate salts of organic bases, alkali metal glutamate salts and alkaline earth metal glutamate salts.

Zhao teaches a method of one step RT-PCR using mixes containing a reverse transcriptase such as an RNase mutant version of M-MLV and a thermostable DNA polymerase, column 2, lines 17-24 and column 4, lines 51-58, and a buffer containing the alkali metal glutamate salt, potassium glutamate, at a concentration resulting in a conductivity in the range of 500 to 20,000 microohms, column 6, lines 18-28).

Zhao does not teach methods of combining multiple reverse transcriptases in a one-step RT-PCR assay, such as M-MLV or AMV reverse transcriptases that are reduced in RNase H activity. Zhao also does not teach a method for amplifying a nucleic acid molecule under conditions which substantially relieve reverse-transcriptase-mediated inhibition of DNA polymerase activity.

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to combine the method of Gerard for performing a one-step RT-PCR assay with improved synthesis of full-length double-stranded cDNA products in a one-step RT-PCR assay (Gerard, paragraph 12, lines 1-9), with that of Zhao who teaches an aqueous buffer for one-step PCR containing monovalent ions such as potassium glutamate to yield a conductivity in the range of 500 to 20,000 microohms (Zhao, column 6, lines 18-28) for use in a reaction mixture for performing both reverse transcription and PCR in one reaction tube to generate large amounts of amplified DNA from a very small amount of RNA template (Zhao, column 2, lines 7-13 and column 10, lines 50-63). Thus, an ordinary practitioner would have been motivated

Art Unit: 1637

to combine the methods of Gerard with those of Zhao since Zhao has optimized conditions for performing one-step RT-PCR using buffers containing monovalent ions such as K-glutamate that result in high yields of product from less than 1 ng of RNA template (Zhao, column 10, lines 50-63), while Gerard provides methods for obtaining high yields of full-length products complementary to the original template. Using such methods would allow cDNA products to be readily produced, analyzed, and quantitated for a variety of medical and forensic purposes, or for generating full-length cDNA molecules to form cDNA libraries from a variety of sources (Gerard, paragraph 12, lines 15-21).

7. Claim 17 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gerard et al. (U.S. Patent Pub. No. 2002/0081581) in view of Austin et al. (U.S. Patent No. 5,817,461).

Gerard teaches the limitations of claims 1-4, 7-12, 18, and 19 as discussed above.

Gerard does not teach a method for amplifying a nucleic acid molecule wherein said buffer further comprises an effective amount of an antifoam compound.

With regard to claim 17, Austin teaches methods of performing polynucleotide enzymatic reactions such as PCR that contain detergents such as Tween, NP-40, and Triton X-100, along with antifoam agents (column 16, line 58 to column 17, line 7).

Austin does not teach methods of combining multiple reverse transcriptases in a one-step RT-PCR assay, such as M-MLV or AMV reverse transcriptases that are reduced in RNase H activity. Austin also does not teach a method for amplifying a

nucleic acid molecule under conditions which substantially relieve reverse-transcriptase-mediated inhibition of DNA polymerase activity.

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to combine the methods of Gerard for performing a one-step RT-PCR assay with improved synthesis of full-length cDNA products in a one-step RT-PCR assay (Gerard, paragraph 12, lines 1-9), and improved yield of amplified double-stranded cDNA products, with that of Austin who teaches physiological-type conditions for performing amplification reactions such as PCR that often include detergents such as Tween, NP-40, and Triton X-100, along with antifoam agents (Austin, column 16, line 58 to column 17, line 7). Thus, an ordinary practitioner would have been motivated to combine the methods of Gerard with those of Austin since performing nucleic acid amplification reactions such as RT-PCR may be improved under more physiological conditions using parameters that are similar to intracellular conditions (Austin, column 16, lines 41-58). Since these may include use of detergents that can cause foaming in reaction tubes or plates that may interfere with analysis or limit product yield, Austin teaches the use of antifoam agents in PCR reactions (column 17, lines 2-7). The use of an antifoam agent may help ensure greater yields of amplified cDNA products that are also similar to or identical in length to the original RNA template. Using such methods would allow cDNA products to be readily produced, analyzed, and quantitated for a variety of medical and forensic purposes, or for generating full-length cDNA molecules to form cDNA libraries from a variety of sources (Gerard, paragraph 12, lines 15-21).

Conclusion


8. Claims 1-19 are rejected. No claims are allowable.


Correspondence

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David C. Thomas whose telephone number is 571-272-3320. The examiner can normally be reached on 5 days, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


David C. Thomas 8/18/06
Patent Examiner
Art Unit 1637


JEFFREY FREDMAN
PRIMARY EXAMINER
9/11/01